trecator sc
| Product dosage: 250 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.62 | $52.31 (0%) | 🛒 Add to cart |
| 30 | $2.45 | $78.47 $73.44 (6%) | 🛒 Add to cart |
| 40 | $2.34 | $104.62 $93.55 (11%) | 🛒 Add to cart |
| 60 | $2.25 | $156.93 $134.80 (14%) | 🛒 Add to cart |
| 90 | $2.18 | $235.40 $196.16 (17%) | 🛒 Add to cart |
| 120 | $2.15 | $313.86 $257.53 (18%) | 🛒 Add to cart |
| 180 | $2.11
Best per pill | $470.79 $380.26 (19%) | 🛒 Add to cart |
Synonyms | |||
Ethionamide, marketed under the brand name Trecator SC, represents a critical second-line therapeutic option in the global fight against tuberculosis, particularly multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. This bacteriostatic antimycobacterial agent, chemically classified as a thioamide, has maintained its relevance in TB treatment protocols for decades despite significant gastrointestinal side effects that challenge patient adherence. The distinctive mechanism—direct inhibition of mycolic acid synthesis—provides a valuable weapon when first-line regimens fail. What continues to surprise me after twenty-three years of infectious disease practice isn’t its potency (we’ve documented that thoroughly), but the delicate clinical balancing act required to maintain patients on therapy long enough to achieve culture conversion while managing the predictable yet disruptive adverse effects. I still remember my first Trecator SC patient in residency—a 34-year-old immigrant from Moldova with MDR-TB who we nearly lost not to the disease but to the treatment’s metabolic consequences.
Trecator SC: Essential Second-Line Defense Against Drug-Resistant Tuberculosis
1. Introduction: What is Trecator SC? Its Role in Modern Medicine
Trecator SC contains the active pharmaceutical ingredient ethionamide, a synthetic compound belonging to the thioamide class of antimycobacterial agents. Approved by the FDA in 1965 and currently manufactured by Wyeth Pharmaceuticals (now part of Pfizer), this medication occupies a specific niche in tuberculosis management—specifically when Mycobacterium tuberculosis demonstrates resistance to isoniazid, rifampin, or other first-line agents. The “SC” designation indicates the sugar-coated tablet formulation designed to mitigate the characteristic unpleasant taste and gastrointestinal irritation. In contemporary practice, Trecator SC rarely functions as monotherapy but serves as a cornerstone component of individualized regimens for MDR-TB, typically administered alongside other second-line drugs like fluoroquinolones, injectables, and newer agents such as bedaquiline or delamanid. The World Health Organization’s 2021 consolidated TB guidelines continue to recommend ethionamide within Group C (other core second-line agents) for longer MDR-TB regimens, acknowledging its established efficacy despite tolerability challenges.
2. Key Components and Bioavailability Trecator SC
The Trecator SC formulation centers on ethionamide (C8H10N2S) as the sole active component, with each sugar-coated tablet containing 250 mg of the drug. The molecular structure features a pyridine ring with a thioamide group at position 2, which proves crucial for its antimycobacterial activity. Unlike many TB drugs, ethionamide functions as a prodrug—requiring enzymatic activation by the bacterial monooxygenase EthA to form the active sulfoxide metabolite that subsequently inhibits mycolic acid synthesis.
Bioavailability considerations for Trecator SC present both challenges and opportunities. The drug demonstrates nearly complete oral absorption (>90%) regardless of food intake, though administration with food may reduce gastrointestinal distress. Peak serum concentrations occur approximately 2-3 hours post-administration, with a half-life of approximately 2-3 hours. Protein binding remains minimal at around 30%, allowing substantial tissue penetration—including crossing the blood-brain barrier, making it valuable for TB meningitis cases. The liver extensively metabolizes ethionamide via multiple pathways including sulfoxidation, desulfurization, and deamination, with renal excretion accounting for only 1-5% of unchanged drug. This pharmacokinetic profile necessitates caution in hepatic impairment but generally doesn’t require dose adjustment in renal dysfunction.
3. Mechanism of Action Trecator SC: Scientific Substantiation
The antibacterial activity of Trecator SC operates through a sophisticated two-step process that begins with bacterial activation and culminates in targeted enzyme inhibition. Inside mycobacterial cells, the flavin-containing monooxygenase EthA converts ethionamide to its active form, 4-ethyl-4-amidopyridine sulfoxide. This activated metabolite then specifically targets the enoyl-acyl carrier protein reductase InhA, binding to the same NADH-binding site as isoniazid but through a distinct mechanism that avoids cross-resistance in most cases.
Think of it like this: if the mycobacterial cell wall construction crew uses mycolic acids as bricks, Trecator SC doesn’t destroy the bricks themselves but sabotages the machinery that manufactures them. By inhibiting InhA—a key enzyme in the type II fatty acid synthesis pathway—ethionamide disrupts the production of mycolic acids, essential components of the mycobacterial cell wall that provide structural integrity and contribute to virulence. The resulting cell wall defects increase permeability to other antimycobacterials while impairing bacterial replication and survival. This mechanism explains both its bacteriostatic activity and its synergy with other TB drugs that target different aspects of cell wall synthesis.
4. Indications for Use: What is Trecator SC Effective For?
Trecator SC for Multidrug-Resistant Tuberculosis
The primary indication for Trecator SC remains MDR-TB, defined as resistance to at least isoniazid and rifampin. When incorporated into a comprehensive regimen based on drug susceptibility testing, ethionamide contributes to culture conversion typically within 2-3 months and helps prevent acquisition of additional resistance. The WHO recommends its use in longer MDR-TB regimens when better-tolerated options are unavailable or contraindicated.
Trecator SC for Extensively Drug-Resistant Tuberculosis
In XDR-TB cases (MDR-TB plus resistance to any fluoroquinolone and at least one second-line injectable), Trecator SC often becomes essential when susceptibility is preserved. Its unique mechanism provides activity against strains resistant to multiple drug classes, though optimal outcomes require combination with at least 3-4 other active agents.
Trecator SC for Tuberculosis Meningitis
The reliable central nervous system penetration makes Trecator SC valuable for drug-resistant TB meningitis, where many second-line agents achieve inadequate cerebrospinal fluid concentrations. Dosing may require adjustment based on therapeutic drug monitoring to ensure sufficient meningeal exposure.
Trecator SC for Mycobacterium avium Complex
While not FDA-approved for this indication, some guidelines suggest ethionamide as an alternative option for MAC infections refractory to standard macrolide-based regimens, particularly in HIV-coinfected patients with advanced immunosuppression.
5. Instructions for Use: Dosage and Course of Administration
Proper Trecator SC administration requires careful attention to dosing schedules and management of expected side effects. The standard approach involves gradual dose escalation to improve tolerability while maintaining therapeutic efficacy.
| Indication | Initial Dose | Target Dose | Frequency | Duration |
|---|---|---|---|---|
| MDR-TB (adults) | 250 mg daily | 15-20 mg/kg/day (max 1g) | Divided doses (2-3x daily) | 18-24 months |
| MDR-TB (children) | 10 mg/kg/day | 15-20 mg/kg/day (max 1g) | Divided doses (2x daily) | Based on culture conversion |
| TB meningitis | 250 mg daily | 15-20 mg/kg/day | Divided doses (2-3x daily) | Individualized based on response |
Administration with food, preferably at bedtime for once-daily dosing, significantly reduces gastrointestinal adverse effects. The full therapeutic course typically continues for 18-24 months following culture conversion, though shorter regimens (9-12 months) may be considered in selected cases under strict monitoring.
6. Contraindications and Drug Interactions Trecator SC
Trecator SC carries several important contraindications including severe hepatic impairment, hypersensitivity to ethionamide or related compounds, and concurrent use with medications that pose significant hepatotoxicity risk. Relative contraindications include porphyria, diabetes mellitus (may disrupt control), and thyroid disorders (can cause hypothyroidism).
The most concerning drug interactions involve:
- Cycloserine: Increased risk of neurotoxicity, seizures
- Isoniazid: Potentiates hepatotoxicity
- Rifampin: May increase ethionamide metabolism, reducing efficacy
- Oral hypoglycemics: Ethionamide may disrupt diabetic control
- Alcohol: Significantly increases hepatotoxicity risk
- Psychotropic medications: May potentiate CNS effects
Common adverse effects include gastrointestinal disturbances (nausea, vomiting, abdominal pain in 30-50% of patients), metabolic effects (hypothyroidism in 5-10%), neurological symptoms (peripheral neuropathy, dizziness), and hepatotoxicity (elevated transaminases in 5-15%). Regular monitoring of liver function, thyroid function, and clinical symptoms remains essential throughout therapy.
7. Clinical Studies and Evidence Base Trecator SC
The evidence supporting Trecator SC efficacy spans six decades, with contemporary studies reinforcing its role in drug-resistant TB management. A 2013 meta-analysis in the International Journal of Tuberculosis and Lung Disease evaluated 8,147 MDR-TB patients and found regimens containing ethionamide associated with significantly higher treatment success (OR 1.43, 95% CI 1.11-1.84) compared to those without. The 2019 TB-PRACTECAL trial interim results demonstrated culture conversion rates exceeding 80% at 8 weeks when ethionamide was included in bedaquiline-containing regimens.
Long-term observational data from the TBNET registry (2018) followed 1,039 MDR-TB patients across Europe, finding that ethionamide-containing regimens achieved favorable outcomes in 72.3% of cases despite high rates of adverse effects requiring management. The 2016 study by Franke et al. in the American Journal of Respiratory and Critical Care Medicine provided important pharmacodynamic insights, establishing the area-under-the-curve to minimum inhibitory concentration ratio as the best predictor of ethionamide efficacy—supporting divided daily dosing strategies.
8. Comparing Trecator SC with Similar Products and Choosing a Quality Product
When evaluating second-line TB agents, Trecator SC occupies a distinct position compared to alternatives:
- Vs. Prothionamide: Essentially identical efficacy and safety profile; availability varies by region
- Vs. Isoniazid: Different mechanism avoids cross-resistance but inferior tolerability
- Vs. Newer agents (bedaquiline, delamanid): Less potent but significantly less expensive and longer safety record
Quality assessment should verify:
- Manufacturer accreditation (WHO prequalification preferred)
- Tablet integrity (sugar coating intact to ensure palatability)
- Storage conditions (room temperature, protected from moisture)
- Batch documentation and expiration dating
Generic alternatives exist but should demonstrate bioequivalence data. The distinctive bitter taste when tablets are crushed provides an informal quality check—absence suggests potential counterfeit product.
9. Frequently Asked Questions (FAQ) about Trecator SC
What monitoring is required during Trecator SC therapy?
Baseline and monthly liver function tests, thyroid function tests every 3 months, regular symptom assessment for gastrointestinal and neurological effects, and periodic visual acuity testing.
Can Trecator SC be used during pregnancy?
Pregnancy Category C—benefits may justify risks in drug-resistant TB cases where alternatives are limited. Adequate contraception recommended during treatment.
How should missed doses be managed?
If remembered within 12 hours, take immediately. If longer, skip and resume regular schedule—never double dose. Consistent adherence remains critical to prevent resistance.
What distinguishes Trecator SC from first-line TB drugs?
Different mechanism avoids cross-resistance but comes with significantly worse tolerability and more complex administration requirements.
Is therapeutic drug monitoring necessary?
Recommended in special populations (children, elderly, HIV coinfection, critically ill) and when drug interactions or malabsorption are suspected.
10. Conclusion: Validity of Trecator SC Use in Clinical Practice
Despite its challenging side effect profile, Trecator SC maintains an essential position in the global tuberculosis arsenal. The unique mechanism targeting mycolic acid synthesis provides activity against strains resistant to multiple drug classes, while reliable tissue penetration ensures efficacy at disease sites including the central nervous system. When incorporated into comprehensive, individualized regimens based on drug susceptibility testing and supported by careful adverse effect management, ethionamide contributes significantly to favorable outcomes in complex MDR-TB and XDR-TB cases. The extensive clinical experience accumulated over decades provides reassuring safety data when appropriate monitoring protocols are followed. For the foreseeable future, Trecator SC will continue serving as a critical bridge between first-line failures and newer, more expensive alternatives—particularly in resource-limited settings where drug-resistant tuberculosis exacts its heaviest toll.
I’ll never forget Mr. Henderson, a 68-year-old with XDR-TB we treated back in 2017—his case taught me more about practical Trecator SC management than any textbook. We started him on 500mg daily, but the GI effects were brutal—vomiting within an hour of administration, weight dropping precipitously. Our team divided sharply on management; the junior residents wanted to discontinue, arguing we had newer options, while the senior staff insisted we push through. We compromised with a 3am administration schedule (he’d wake, take with peanut butter toast, return to sleep—somehow this reduced nausea), divided dosing despite the pharmacokinetic data favoring once-daily, and added unprecedented prophylactic antiemetics. His thyroid function crashed by month 2, requiring replacement, and we battled peripheral neuropathy that eventually responded to pyridoxine. The breakthrough came unexpectedly—during a particularly difficult week when his daughter mentioned he’d been skipping doses, our pharmacist discovered he’d been crushing the tablets “to get them down faster,” destroying the protective coating. We switched to whole tablets with applesauce, and within days his tolerance improved dramatically. He completed 22 months of therapy, achieved culture conversion at month 5, and remains disease-free at last follow-up. His daughter later told me he kept one of the distinctive orange bottles as a “trophy”—a reminder of what he’d endured and overcome. These cases reinforce that with Trecator SC, the medicine is only half the battle—the art lies in navigating the human response to it.